On 22 March, Roche announced that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys® Amyloid Plasma Panel (EAPP). The EAPP is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease (AD). The test measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau181 occur in early stages of AD, while the presence of APOE4 constitutes the most common genetic risk factor for AD. The Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation. In July, Roche announced that the US Food and Drug Administration (FDA) granted the EAPP Breakthrough Device Designation. If approved, the test would be an additional tool to determine whether patients should receive further evaluation that may confirm a diagnosis and could help them access new therapies as they become available, the company said.
Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease